Edition:
United Kingdom

Abeona Therapeutics Inc (ABEO.OQ)

ABEO.OQ on NASDAQ Stock Exchange Capital Market

20.90USD
20 Apr 2018
Change (% chg)

$0.85 (+4.24%)
Prev Close
$20.05
Open
$20.30
Day's High
$21.65
Day's Low
$20.10
Volume
201,372
Avg. Vol
264,708
52-wk High
$22.70
52-wk Low
$4.55

Chart for

About

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin... (more)

Overall

Beta: 1.29
Market Cap(Mil.): $977.60
Shares Outstanding(Mil.): 46.78
Dividend: --
Yield (%): --

Financials

  ABEO.OQ Industry Sector
P/E (TTM): -- 188.22 33.60
EPS (TTM): -0.65 -- --
ROI: -19.80 -0.74 13.19
ROE: -20.30 -2.80 15.00

BRIEF-Abeona Therapeutics Receives Orphan Drug Designation In The European Union For ABO-202 Gene Therapy Program In Batten Disease

* ABEONA THERAPEUTICS RECEIVES ORPHAN DRUG DESIGNATION IN THE EUROPEAN UNION FOR ABO-202 GENE THERAPY PROGRAM IN BATTEN DISEASE Source text for Eikon: Further company coverage:

20 Apr 2018

BRIEF-Abeona Therapeutics Appoints Carsten Thiel, Ph.D., As Chief Executive Officer

* ABEONA THERAPEUTICS APPOINTS CARSTEN THIEL, PH.D., AS CHIEF EXECUTIVE OFFICER

02 Apr 2018

BRIEF-Abeona Therapeutics Appoints Carsten Thiel As Chief Executive Officer

* TIMOTHY J. MILLER WILL REMAIN PRESIDENT AND ASSUME POSITION OF CHIEF SCIENTIFIC OFFICER Source text for Eikon: Further company coverage:

02 Apr 2018

BRIEF-Abeona Therapeutics Reports Q4 Loss Per Share $0.19

* ABEONA THERAPEUTICS REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS

16 Mar 2018

BRIEF-Abeona Receives FDA Rare Pediatric Disease Designation For ABO-202 Gene Therapy Program In CLN1 Disease

* ABEONA THERAPEUTICS RECEIVES FDA RARE PEDIATRIC DISEASE DESIGNATION FOR ABO-202 GENE THERAPY PROGRAM IN CLN1 DISEASE

15 Mar 2018

BRIEF-Abeona Receives FDA Orphan Drug Status For Gene Therapy To Treat Rare Disease In Newborns

* ABEONA THERAPEUTICS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR ABO-202 GENE THERAPY PROGRAM IN INFANTILE BATTEN DISEASE

12 Feb 2018

BRIEF-Abeona Therapeutics Says Gene Therapy ABO-101 Is Well Tolerated

* ABEONA THERAPEUTICS REPORTS ON INITIAL SAFETY AND BIOPOTENCY SIGNALS IN MPS IIIB GENE THERAPY CLINICAL TRIAL

07 Feb 2018

BRIEF-Abeona Receives FDA Regenerative Medicine Advanced Therapy Status For Experimental Gene Therapy For Rare Skin Disorder

* ABEONA RECEIVES FDA REGENERATIVE MEDICINE ADVANCED THERAPY DESIGNATION FOR EB-101 GENE THERAPY IN EPIDERMOLYSIS BULLOSA

29 Jan 2018

BRIEF-Abeona Q3 loss per share $0.13

* Abeona reports third quarter 2017 financial results and recent business highlights

15 Nov 2017

Earnings vs. Estimates